AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06123702
Drug: Cannabidiol Cap/Tab
RxNorm normalized name: CANNABIDIOL CAP/TAB
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 50-mg capsules
Trial: NCT05304845
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid
Trial: NCT04814485
Drug: SHR-1020+albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
Trial: NCT05572645
Drug: Pyrotinib Plus Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Trial: NCT05572645
Drug: Pertuzumab Plus Trastuzumab
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Trial: NCT00215397
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05857267
Drug: Dorzolamide / Timolol Ophthalmic Solution
RxNorm normalized name: dorzolamide / timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dorzolamide-timolol fixed combination in a preservative-free multidose device
Trial: NCT05857267
Drug: dorzolamide/timolol
RxNorm normalized name: DORZOLAMIDE/TIMOLOL
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dorzolamide-timolol BAK-preserved fixed combination
Trial: NCT00537953
Drug: Miltefosine , meglumine antimoniate
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05893862
Drug: MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05893862
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06354218
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab （4.5mg/Kg every 3 weeks）
Trial: NCT05627518
Drug: Linaprazan glurate
RxNorm normalized name: calcium glucarate
DrugBank: Calcium saccharate (DB13962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg
Trial: NCT05947669
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
Trial: NCT05947669
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
Trial: NCT05705830
Drug: Selective serotonin reuptake inhibitors （SSRI）
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-anxiety Drugs
Trial: NCT06281899
Drug: Dapagliflozin 10 mg Tab
RxNorm normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once daily
Trial: NCT04723238
Drug: Duloxetine 60mg Test Drug Enteric Coated Granules
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT04723238
Drug: Duloxetine 60mg Reference Product Enteric Coated Granules
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cymbalta (Eli Lilly)
Trial: NCT04715165
Drug: USG-STAP with bupivacaine and dexmedetomidine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
Trial: NCT04715165
Drug: IP bupivacaine and dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
Trial: NCT05027633
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given by IV
Trial: NCT05027633
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given by IV
Trial: NCT05027633
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given by IV
Trial: NCT05027633
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given by IV
Trial: NCT05804370
Drug: Gleolan
RxNorm normalized name: Gleolan
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
Trial: NCT06385171
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
Trial: NCT05994547
Drug: Byfavo
RxNorm normalized name: Byfavo
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT05994547
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT04731103
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets or oral solution
Trial: NCT04731103
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet or oral solution
Trial: NCT04731103
Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
RxNorm normalized name: abacavir / lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or oral solution
Trial: NCT00000719
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000719
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05562167
Drug: KNO3
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
Trial: NCT04887064
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib will be administered as an oral tablet.
Trial: NCT04743791
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
Trial: NCT04777201
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
Trial: NCT06420388
Drug: 2% Lidocaine Gel
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications.
Trial: NCT06420388
Drug: Water-based Lubricant Gel (K-Y Gel)
RxNorm normalized name: benzoyl peroxide
DrugBank: Water (DB09145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
Trial: NCT04617275
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-68882961 will be provided as tablets twice a day (BID)
Trial: NCT05922501
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
Trial: NCT05922501
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
Trial: NCT05922501
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An immunomodulatory agent, capsule taken orally.
Trial: NCT05922501
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
Trial: NCT00269945
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05061420
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
Trial: NCT05061420
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
Trial: NCT05119179
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon-like Peptide 1 Receptor Agonist
Trial: NCT06071897
Drug: monoclonal antibodies GD2
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy
Trial: NCT06729047
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
Trial: NCT06727838
Drug: HRS-7535 tablets
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-7535 tablets.
Trial: NCT06727838
Drug: Metformin Hydrochloride Extended-release Tablets
RxNorm normalized name: Metformin Hydrochloride Extended-Release Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride Extended-release Tablets.
Trial: NCT06727838
Drug: Metformin Hydrochloride Tablets
RxNorm normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride Tablets.
Trial: NCT06728839
Drug: 1L PEG + 50g magnesium sulfate
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.
Trial: NCT06728839
Drug: 3L PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
Trial: NCT06728839
Drug: 4L PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
Trial: NCT06729034
Drug: Apixaban (Eliquis)
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg twice daily
Trial: NCT06729086
Drug: sedation using propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.
Trial: NCT06729086
Drug: sedation using sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
Trial: NCT04745104
Drug: SHR-1707
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1707 will be administered through IV infusion
Trial: NCT05746208
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT05746208
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01446120
Drug: NPH-Insulin Injection
RxNorm normalized name: Neutral Protamine Hagedorn (NPH) insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05043766
Drug: PF614
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PF614 is an oxycodone prodrug
Trial: NCT05043766
Drug: Naltrexone Hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
Trial: NCT05043766
Drug: OxyContin
RxNorm normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bioequivalence single-dose comparison to OxyContin
Trial: NCT04071470
Drug: PrEP
RxNorm normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
Trial: NCT06160713
Drug: Itraconazole 65 MG
RxNorm normalized name: itraconazole 65 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules of suba-itraconazole 65 mg twice daily for 6 months
Trial: NCT06426212
Drug: Use of teicoplanin three times a week
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
Trial: NCT06455735
Drug: 68Ga-JH04
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
Trial: NCT06030804
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Trial: NCT02652325
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02652325
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02652325
Drug: 5% Povidone-Iodine USP swabs
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04807673
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
Trial: NCT04807673
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
Trial: NCT05452174
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
Trial: NCT05776043
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily for 6 or 9 months
Trial: NCT05776043
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily for 6 or 9 months
Trial: NCT05009953
Drug: Irinotecan Liposome Injection
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
Trial: NCT05009953
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
Trial: NCT05588531
Drug: Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
Trial: NCT00002192
Drug: Rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002192
Drug: Ethambutol hydrochloride
RxNorm normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05558319
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib
Trial: NCT05558319
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab
Trial: NCT05558319
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide
Trial: NCT05558319
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide